Press release

DiaCarta, Ltd Raises $45 Million USD Series B Funding to Expand Its Liquid Biopsy Cancer Detection Platform & Services

Feb 12, 2018 | Press Releases

DiaCarta has announced that it has completed its Series B funding round, realizing a total of $45.0M USD. The second closing was led by Fortune Fountain Capital (FFC) and was also subscribed to by Good Health Capital (GHC).

Commenting on the announcement, Aiguo (Adam) Zhang, Ph.D., Founder and CEO of DiaCarta, stated, “The Series B financing will support the Company’s core XNA technology platform for early cancer detection, expanding our diagnostic products for non-invasive early detection and monitoring of cancers. In addition, we will be strengthening our comprehensive IP position, expanding further into global markets with concomitant applications for FDA and CFDA certifications. DiaCarta is very pleased to add FFC and GHC to our family who shares our vision to build a world-leading molecular diagnostic company that will impact patient health.”

The funds raised in this financing round will be used to drive profitable growth in the following areas:

  1. Setting up global clinical study programs for non-Invasive Early Cancer detection to include Recurrence and Monitoring indications;
  2. The commercial launch of ColoScape™, a highly sensitive in vitro diagnostic assay for the detection of colorectal cancer in liquid biopsy and tissue samples;
  3. Expansion of product development pipeline to include a range of gene mutation and fusion panels using core technology platforms in DNA low frequency mutation detection; and a highly sensitive next generation of multiplexing HPV (Human papillomavirus) genotyping E6/E7 mRNA test, etc;
  4. Expansion of DiaCarta’s CLIA & OptiSeq™ Next Generation Sequencing offerings;
  5. Strengthening core IP position and applications for FDA and CFDA certifications for relevant tests;
  6. Expansion of commercial team and relevant support roles to meet the demands and challenges of a growing product portfolio within global market channels.

About DiaCarta:

DiaCarta’s mission is to provide its customers with molecular diagnostic tests and NGS services that are reliable, highly sensitive, low cost, and work with both tissue and liquid biopsy samples that impact treatment plans that strive to improve the well-being of patients.

DiaCarta is focused on genomic innovation through detection and amplification technologies headquartered in Richmond, California. The company has an ISO 13485-certified facility, which is used to develop, manufacture and market a range of cancer research and IVD products. DiaCarta specializes in genomic testing for biomarkers and offers clinical sample testing services in a CLIA-certified laboratory. In addition, the company has a clinical service laboratory in Nanjing, China. QClamp® and OptiSeq™ are patented xeno nucleic acid (XNA™) based technologies that enable highly sensitive detection of actionable mutations using qPCR and next-generation sequencing (NGS) platforms on challenging patient specimens. Other XNA applications include CRISPR/Cas9 gene-editing event screening and adapter dimer removal for NGS library preparation. To learn more, visit https://www.diacarta.com.

Technology Platform

The novel QClamp® Xeno-Nucleic Acid (XNA™) clamping technology has solved the interference bottleneck of wild-type DNA in gene mutation detection and has successfully enhanced the sensitivity and specificity in the detection process, especially in the liquid biopsy field. The technology can be widely used in quantitative PCR (qPCR), gene chip, nanotechnology and all generations of NGS platforms and is underpinned by over 80 patents.

Lead Source

DiaCarta and Capstone Health Alliance Collaborate to Bring Revolutionary Diagnostic Tests to Enhance Patient Care

DiaCarta, Inc., a pioneer in developing innovative molecular technologies to transform patient care by providing effective precision diagnostics using liquid biopsy in cancer and infectious diseases has established a strategic collaboration with Capstone Health Alliance, one of the largest regional group purchasing organizations (GPO) in the US healthcare sector. This new collaboration brings together powerful technologies to enhance patient care.

Florida Selects DiaCarta’s cfDNA Test (RadTox™) for Statewide Use to Detect Early Response of Cancer Treatment

DiaCarta, a leading molecular diagnostics company specializing in personalized patient care through liquid biopsy, proudly announced that Florida Health Department selected “using plasma DNA concentration (DiaCarta’s RadTox™ test) for early detection of treatment response and resistance” through the Casey DeSantis Florida Cancer Innovation Fund. This fund supports deployment of the RadTox™ test throughout the State of Florida to be performed between Radiotherapy or Chemotherapy doses for real time detection of treatment response or resistance. The results will be as a real time predictor of imaging data.

DiaCarta, Inc. and OncoAssure Ltd. Collaborate to Launch Prostate Cancer Lab Developed Test

DiaCarta, Inc. (“DiaCarta”), a pioneer in molecular diagnostic test development for cancer and infectious diseases, today announced that it has established a strategic collaboration with OncoAssure Ltd, an Irish medical diagnostics company. The focus of the collaboration is to commercialize OncoAssure’s groundbreaking Prostate test which is designed to identify patients with a lower risk of prostate cancer recurrence, guiding decisions on active surveillance or reduced monitoring post-treatment.

X